Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Eyes on Topical Ocular Disposition: The Considered Design of a Lead Janus Kinase (JAK) Inhibitor That Utilizes a Unique Azetidin-3-Amino Bridging Scaffold to Attenuate Off-Target Kinase Activity, While Driving Potency and Aqueous Solubility.
Gordhan HM, Miller ST, Clancy DC, Ina M, McDougal AV, Cutno DK, Brown RV, Lichorowic CL, Sturdivant JM, Vick KA, Williams SS, deLong MA, White JC, Kopczynski CC, Ellis DA. Gordhan HM, et al. Among authors: mcdougal av. J Med Chem. 2023 Jul 13;66(13):8929-8950. doi: 10.1021/acs.jmedchem.3c00519. Epub 2023 Jun 14. J Med Chem. 2023. PMID: 37314941
Discovery and Preclinical Development of Novel Intraocular Pressure-Lowering Rho Kinase Inhibitor: Corticosteroid Conjugates.
Sturdivant J, Williams SS, Ina M, Weksler M, McDougal A, Clancy D, deLong MA, Girouard N, Zaretskaia M, Brennan K, Glendenning A, Foley B, Lin CW, White JC, Kopczynski C, Kelly CR. Sturdivant J, et al. J Ocul Pharmacol Ther. 2023 Mar;39(2):117-127. doi: 10.1089/jop.2022.0129. Epub 2023 Jan 4. J Ocul Pharmacol Ther. 2023. PMID: 36602977
The exploration of aza-quinolines as hematopoietic prostaglandin D synthase (H-PGDS) inhibitors with low brain exposure.
Cadilla R, Deaton DN, Do Y, Elkins PA, Ennulat D, Guss JH, Holt J, Jeune MR, King AG, Klapwijk JC, Kramer HF, Kramer NJ, Laffan SB, Masuria PI, McDougal AV, Mortenson PN, Musetti C, Peckham GE, Pietrak BL, Poole C, Price DJ, Rendina AR, Sati G, Saxty G, Shearer BG, Shewchuk LM, Sneddon HF, Stewart EL, Stuart JD, Thomas DN, Thomson SA, Ward P, Wilson JW, Xu T, Youngman MA. Cadilla R, et al. Among authors: mcdougal av. Bioorg Med Chem. 2020 Dec 1;28(23):115791. doi: 10.1016/j.bmc.2020.115791. Epub 2020 Oct 3. Bioorg Med Chem. 2020. PMID: 33059303
Correction to: HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction induced injury.
Billin AN, Honeycutt SE, McDougal AV, Kerr JP, Chen Z, Freudenberg JM, Rajpal DK, Luo G, Kramer HF, Geske RS, Fang F, Yao B, Clark RV, Lepore J, Cobitz A, Miller R, Nosaka K, Hinken AC, Russell AJ. Billin AN, et al. Among authors: mcdougal av. Skelet Muscle. 2018 Dec 10;8(1):38. doi: 10.1186/s13395-018-0185-7. Skelet Muscle. 2018. PMID: 30526662 Free PMC article.
HIF prolyl hydroxylase inhibition protects skeletal muscle from eccentric contraction-induced injury.
Billin AN, Honeycutt SE, McDougal AV, Kerr JP, Chen Z, Freudenberg JM, Rajpal DK, Luo G, Kramer HF, Geske RS, Fang F, Yao B, Clark RV, Lepore J, Cobitz A, Miller R, Nosaka K, Hinken AC, Russell AJ. Billin AN, et al. Among authors: mcdougal av. Skelet Muscle. 2018 Nov 13;8(1):35. doi: 10.1186/s13395-018-0179-5. Skelet Muscle. 2018. PMID: 30424786 Free PMC article. Clinical Trial.